Gregor Langus

Gregor Langus is the founder of CompetitionSphere, a competition policy group based in Brussels. He is recognized as a leading expert in competition policy by 2021 Who’s Who Legal – a publication by Law Business Research Limited. Recently, Gregor has been focusing on the economic analysis of innovation, digital markets, and intellectual property.

Gregor has advised clients and submitted written testimony in many antitrust investigations, damage disputes, and merger reviews in multiple jurisdictions, involving the European Commission, the U.S. authorities, and the competition authorities of several European Union member states. Gregor is also the lead author of a series of studies on policy in relation to copyright and regulation of telecommunications for the EC.

He holds a doctorate in Economics from the European University Institute and has published on competition policy and economics in journals such as the Journal of Industrial Economics, International Journal of Industrial Organization, Economics Letters, the Journal of Competition Law and Economics, and Concurrences.

Before founding CompetitionSphere, Gregor was a Director at E.CA and prior to that a senior vice president with Compass Lexecon. He has also served in the Chief Economist’s Team (CET) in DG Competition at the European Commission. He has previous consultancy experience and was also a post-doctoral researcher and a lecturer in Microeconomics at the Tilburg University School of Economics.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More